Overview

• Recent trials combining TD-GC-MS sebum profiling and canine detection have achieved up to 80% sensitivity and 98% specificity in distinguishing Parkinson’s patients from controls.
• Researchers have identified 55 volatile organic compounds in skin sebum that vary between healthy individuals, iRBD patients and those with Parkinson’s, establishing a distinct biomarker signature.
• Three-year longitudinal sampling led by Dr Drupad Trivedi has revealed patterns in sebum markers that could map disease progression and inform treatment adjustments.
• Sebum can be collected via simple gauze swabs from the face or upper back without cold storage, offering a cost-effective approach for routine clinical screening.
• Teams are launching multicenter trials across diverse populations and recruiting additional hyperosmic volunteers to validate and refine odor-based detection methods.